ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 939

Stimulator of Interferon Genes (STING)-Induced Endothelial-Mesenchymal Transition (EndMT) Contributes to Interstitial Lung Disease in Sting-Associated Vasculopathy with Onset in Infancy (SAVI) Patients

Louise Malle1, Dan Yang2, Adriana Almeida de Jesus1, Guibin Chen2, Bernadette Marrero1, Gina A. Montealegre Sanchez1, Yin Liu3, Gregor Dueckers4, Suzanne Ramsey5, Joseph Fontana6, Rachel VanTries1, Yan Huang1, Laisa Santiago7, Benito Gonzalez8, Paul Brogan9, Juergen Brunner10, Ebun Omoyinmi11, Athimalaipet V. Ramanan12, Amy Paller13, Olcay Y. Jones14, Seza Ozen15, Stephen R. Brooks16, Manfred Boehm17 and Raphaela Goldbach-Mansky1, 1Translational Autoinflammatory Disease Studies (TADS), Laboratory of Clinical Investigation and Microbiology (LCIM), NIAID/NIH, Bethesda, MD, 2Center for Molecular Medicine, NHLBI/NIH, Bethesda, MD, 3Scientific Review Branch, NIAMS/NIH, Bethesda, MD, 4Helios Kliniken - Kinderklinik, HELIOS Klinikum Krefeld, Krefeld, Germany, 5Pediatric Rheumatology, IWK Health Centre, Dalhousie University, Halifax, NS, Canada, 6Cardiovascular and Pulmonary Branch, NHLBI/NIH, Bethesda, MD, 7Johns Hopkins All Children's Hospital Rheumatology, Saint Petersburg, FL, 8Luis Calvo Mackenna Hospital, Santiago, Chile, 9Infection Inflammation and Rheumatology, UCL Institute of Child Health, and Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom, 10Division of Pediatric Rheumatology, Medical University Innsbruck, Innsbruck, Austria, 11University College London Institute of Child Health, London, United Kingdom, 12Bristol Royal Hospital for Children, Bristol, United Kingdom, 13Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, IN, 14Department of Pediatrics, Walter Reed National Military Medical Center, Bethesda, MD, 15Department of Pediatrics, Division of Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey, 16Biodata Mining and Discovery Section, Office of Science and Technology, NIAMS/NIH, Bethesda, MD, 17Center for Molecular Medicine, NHLBI/ NIH, Bethesda, MD

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Autoinflammation, endothelial cells, fibrosis and interferons, Lung Disease

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 5, 2017

Title: Pediatric Rheumatology – Pathogenesis and Genetics

Session Type: ACR Concurrent Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose: Pulmonary fibrosis, is a life-threatening complication of the monogenic autoinflammatory interferonopathy, STING-Associated Vasculopathy with onset in Infancy (SAVI) that is caused by gain-of-function mutations in the viral sensor/adaptor TMEM173/STING. Pathogenic mechanisms causing fibrosis and factors modifying the onset and severity of lung fibrosis in SAVI patients (pts.) are unknown. Here we show that STING-mediated endothelial cell activation induces an endothelial-mesenchymal transition (EndMT)-like differentiation program that causes lung fibrosis in SAVI pts.

Methods: To understand the role of STING signaling in pulmonary fibrosis, we assessed chest computed tomography (CT), pulmonary function tests (PFTs) in 13 SAVI patients (pts.), and lung histopathology was available from 4 pts. We conducted pts. and control fibroblast, human lung and umbilical vein endothelial cell (EC) lines (HMVEC-L and HUVECs, respectively) and pts. and control induced pluripotent stem cell (iPSC)-derived EC stimulations with endogenous and microbial cGAMP plus/minus IFNb. Gene expression (q-RT-PCR, RNA-seq), cytokine production, and EndMT (by cell morphology and gene expression studies), were assessed. Pts. were genotyped for a common STING SNP (R232H, rs1131769) and the modifying effect of the variant was examined in transfection studies in HEK293T cells.

Results: Of 13 SAVI pts., 10 had severe lung disease, 4 succumbed to pulmonary complications. Pulmonary findings included hilar lymphadenopathy, diffuse ground glass opacities and cystic emphysematous changes on chest CT, and reduced diffusing lung capacity for carbon monoxide (DLCO) and abnormal 6-minute walk test on PFTs. In contrast to control lung biopsies (n=5), pts.’ biopsies (n=4) displayed perivascular fibrosis on Masson’s trichrome-stain around medium-sized and small alveolar vessels. In pts., endothelial lining co-expressed mesenchymal (α-SMA) and stromal fibroblast (FSP-1) markers within the subendothelial compartment. cGAMP stimulation in pt. and control fibroblasts showed no expression of myofibroblast and extracellular matrix (ECM) markers by RNA-seq and q-RT-PCR. Endogenous cGAMP stimulation on HMVEC-L induced morphologic transition to fibroblasts with a decreased expression of EC markers CDH5 (V-cadherin), VWF and PECAM1 (CD31), and an increased expression of the mesenchymal markers ACTA2 (α-SMA) and FAP and of the stromal fibroblast marker S100A4 (FSP-1). IFNβ and cGAMP stimulation synergize and addition of a JAK inhibitor attenuated the mesenchymal transformation. IPSC-derived EC (iEC) from 4 SAVI pts. but not HCs spontaneously differentiated into myofibroblasts in culture. Differentiation was attenuated by JAK inhibition and in shRNA STING knock down iEC. Homozygosity for R232/R232, a STING SNP associated with increased IFNβ production, in addition to the SAVI STING mutation led to a more severe clinical lung phenotype in SAVI patients.

Conclusion: We suggest a novel pathway of STING-mediated ECs activation to induce EndMT-like mesenchymal transformation as cause for lung fibrosis in SAVI pts.


Disclosure: L. Malle, None; D. Yang, None; A. Almeida de Jesus, None; G. Chen, None; B. Marrero, None; G. A. Montealegre Sanchez, Eli Lilly and Company, 9; Y. Liu, None; G. Dueckers, None; S. Ramsey, None; J. Fontana, None; R. VanTries, None; Y. Huang, None; L. Santiago, None; B. Gonzalez, None; P. Brogan, None; J. Brunner, None; E. Omoyinmi, None; A. V. Ramanan, None; A. Paller, None; O. Y. Jones, None; S. Ozen, None; S. R. Brooks, None; M. Boehm, None; R. Goldbach-Mansky, Eli Lilly and Company, 9,SOBI, 9,Regeneron, 9,Novartis Pharmaceutical Corporation, 9.

To cite this abstract in AMA style:

Malle L, Yang D, Almeida de Jesus A, Chen G, Marrero B, Montealegre Sanchez GA, Liu Y, Dueckers G, Ramsey S, Fontana J, VanTries R, Huang Y, Santiago L, Gonzalez B, Brogan P, Brunner J, Omoyinmi E, Ramanan AV, Paller A, Jones OY, Ozen S, Brooks SR, Boehm M, Goldbach-Mansky R. Stimulator of Interferon Genes (STING)-Induced Endothelial-Mesenchymal Transition (EndMT) Contributes to Interstitial Lung Disease in Sting-Associated Vasculopathy with Onset in Infancy (SAVI) Patients [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/stimulator-of-interferon-genes-sting-induced-endothelial-mesenchymal-transition-endmt-contributes-to-interstitial-lung-disease-in-sting-associated-vasculopathy-with-onset-in-infancy-savi-patient/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/stimulator-of-interferon-genes-sting-induced-endothelial-mesenchymal-transition-endmt-contributes-to-interstitial-lung-disease-in-sting-associated-vasculopathy-with-onset-in-infancy-savi-patient/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology